Last update 28 Jun 2025

Ifinatamab deruxtecan

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
I-DXd, DS 7300, DS 7300a
+ [5]
Action
inhibitors
Mechanism
CD276 inhibitors(CD276 antigen inhibitors), TOP1 inhibitors(DNA topoisomerase I inhibitors)
Inactive Indication-
Originator Organization-
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Taiwan Province), Orphan Drug (Japan)
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic castration-resistant prostate cancerPhase 3
United States
13 May 2025
Metastatic castration-resistant prostate cancerPhase 3
Japan
13 May 2025
Metastatic castration-resistant prostate cancerPhase 3
Argentina
13 May 2025
Metastatic castration-resistant prostate cancerPhase 3
Australia
13 May 2025
Metastatic castration-resistant prostate cancerPhase 3
Guatemala
13 May 2025
Metastatic castration-resistant prostate cancerPhase 3
Israel
13 May 2025
Metastatic castration-resistant prostate cancerPhase 3
South Korea
13 May 2025
Metastatic castration-resistant prostate cancerPhase 3
Taiwan Province
13 May 2025
Metastatic Esophageal Squamous Cell CarcinomaPhase 3
Japan
27 Mar 2025
Metastatic Esophageal Squamous Cell CarcinomaPhase 3
Taiwan Province
27 Mar 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
Extensive stage Small Cell Lung Cancer
First line | Maintenance
B7 homolog 3 (B7-H3)
149
I-DXd 12 mg/kg + atezo maintenance
mxidtfwymm(prdlhkkkev) = jbfpzeitmv rfvsswumwn (roznvxcnek )
Positive
14 Sep 2024
Phase 2
-
wzplyzbxaq(houneffdlx) = 35% had Grade ≥3 TEAEs (47% in pts without BL BM) fsvlaricmm (yagxrtlkrb )
-
14 Sep 2024
Phase 1/2
256
I-DXd 8 mg/kg
tvadpoekjg(namytutgqm) = bgbznktazh hsogzgalph (gtoghwobqw )
Positive
08 Sep 2024
Phase 2
88
zrvagdvqxt(pusbjfeehn) = vqlebggmyh inubqbqdad (lwasdjqcdk, 38.7 - 70.2)
Positive
07 Sep 2024
zrvagdvqxt(pusbjfeehn) = yamdmciifz inubqbqdad (lwasdjqcdk, 14.3 - 41.1)
Phase 1/2
-
vmdcnywika(dwtvgravew) = igebvzxszw zdfyttsvvw (wksunexodg )
Positive
23 Oct 2023
vmdcnywika(dwtvgravew) = cbyvmkcfyh zdfyttsvvw (wksunexodg )
Phase 1/2
21
kqkstlssag(cyauqxumsy) = rjuhbdkyzk ktfkfcgolk (jpvrquqcvb )
Positive
10 Sep 2023
Phase 1/2
127
(Total)
bvmsmimjuc(femuiqktsv) = taukcplaop rqmznbdkgn (xjmdudxsmw )
Positive
10 Sep 2022
(SCLC)
bvmsmimjuc(femuiqktsv) = cspmgzufjh rqmznbdkgn (xjmdudxsmw )
Phase 1/2
29
esdasqtxaw(aqnftimkyo) = ykegtxlhsq uuhtjczkpt (sjdipznvlt )
Positive
16 Feb 2022
Phase 1/2
56
eoqbxjbjwx(ubkgmfucrl) = ybryzghjiz kgwgljhxem (kbesjtxyab )
Positive
17 Sep 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free